Skip to main content

Antibody Labeling with Radioiodine and Radiometals

  • Protocol
  • First Online:
Drug Delivery System

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1141))

Abstract

Antibodies have been conjugated to radionuclides for various in vitro and in vivo applications. Radiolabeled antibodies have been used in clinics and research for diagnostic applications both in vitro as reagents in bioassays and in vivo as imaging agents. Further, radiolabeled antibodies are used as direct therapeutic agents for cancer radioimmunotherapy or as tracers for studying the pharmacokinetics and biodistribution of therapeutic antibodies. Antibodies are labeled with radiohalogens or radiometals, and the choice of candidate radionuclides for a given application is dictated by their emission range and half-life. The conjugation chemistry for the coupling of MAbs with the radiometals requires a chelator, whereas radiohalogens can be incorporated directly in the antibody backbone. In this chapter, we describe the commonly used methods for radiolabeling and characterizing the antibodies most commonly used radiohalogens (125I/131I) and radiometals (177Lu/99mTc).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Milenic DE, Brady ED, Brechbiel MW (2004) Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 3:488–499

    Article  CAS  Google Scholar 

  2. O’Donoghue JA, Bardies M, Wheldon TE (1995) Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 36:1902–1909

    Google Scholar 

  3. Makrigiorgos G, Adelstein SJ, Kassis AI (1990) Auger electron emitters: insights gained from in vitro experiments. Radiat Environ Biophys 29:75–91

    Article  CAS  Google Scholar 

  4. Chauhan SC, Jain M, Moore ED, Wittel UA, Li J, Gwilt PR, Colcher D, Batra SK (2005) Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49. Eur J Nucl Med Mol Imaging 32:264–273

    Article  CAS  Google Scholar 

  5. Batra SK, Jain M, Wittel UA, Chauhan SC, Colcher D (2002) Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol 13:603–608

    Article  CAS  Google Scholar 

  6. Jain M, Kamal N, Batra SK (2007) Engineering antibodies for clinical applications. Trends Biotechnol 25:307–316

    Article  CAS  Google Scholar 

  7. Anderson WT, Strand M (1987) Radiolabeled antibody: iodine versus radiometal chelates. NCI Monogr 3:149–151

    Google Scholar 

  8. Colcher D, Zalutsky M, Kaplan W, Kufe D, Austin F, Schlom J (1983) Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody. Cancer Res 43:736–742

    CAS  Google Scholar 

  9. Abrams MJ, Juweid M, TenKate CI, Schwartz DA, Hauser MM, Gaul FE, Fuccello AJ, Rubin RH, Strauss HW, Fischman AJ (1990) Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med 31:2022–2028

    CAS  Google Scholar 

  10. Goel A, Baranowska-Kortylewicz J, Hinrichs SH, Wisecarver J, Pavlinkova G, Augustine S, Colcher D, Booth BJ, Batra SK (2001) 99mTc-labeled divalent and tetravalent CC49 single-chain Fv’s: novel imaging agents for rapid in vivo localization of human colon carcinoma. J Nucl Med 42:1519–1527

    CAS  Google Scholar 

  11. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685

    Article  CAS  Google Scholar 

  12. Hens M, Vaidyanathan G, Welsh P, Zalutsky MR (2009) Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands. Nucl Med Biol 36:117–128

    Article  CAS  Google Scholar 

  13. Hens M, Vaidyanathan G, Zhao XG, Bigner DD, Zalutsky MR (2010) Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands. Nucl Med Biol 37:741–750

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors on this work are supported, in part, by grants from the National Institutes of Health P20GM103480, R21 CA156037, U01CA111294, R03 CA 139285, R03 CA167342, P50 CA127297, and U54163120.

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media, New York

About this protocol

Cite this protocol

Gupta, S., Batra, S., Jain, M. (2014). Antibody Labeling with Radioiodine and Radiometals. In: Jain, K. (eds) Drug Delivery System. Methods in Molecular Biology, vol 1141. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-0363-4_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-0363-4_9

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-0362-7

  • Online ISBN: 978-1-4939-0363-4

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics